Pharmaceutical company Pozen Inc. (POZN), Monday said the US Court of Appeals for the Federal Circuit has upheld a favorable litigation decision passed by US District Court for the Eastern District of Texas.
The Texas court had issued a favorable verdict for Pozen on August 5, 2011 in the litigation between Pozen and several generic pharmaceutical companies which had filed Abbreviated New Drug Applications seeking approval from the FDA to market generic copies of Treximet.
Treximet is marketed by Pozen's exclusive US licensee GlaxoSmithKline.
"We are pleased that the Court of Appeals has upheld the Eastern District of Texas' ruling in favor of POZEN, thus upholding the patents protecting Treximet," said Chief Executive John Plachetka.
For comments and feedback: editorial@rttnews.com